Cordes L M, Gulley J L
Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Drugs Today (Barc). 2017 Jul;53(7):377-383. doi: 10.1358/dot.2017.53.7.2654888.
Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin. Until the recent approval of avelumab (Bavencio), no therapies were approved by the U.S. Food and Drug Administration for the treatment of metastatic Merkel cell carcinoma. In a recent trial, avelumab, an anti-programmed death ligand-1 antibody, demonstrated an objective response in 28 of 88 patients (31.8% [95.9% CI, 21.9-43.1]) with advanced, chemotherapy-refractory Merkel cell carcinoma. Overall, avelumab was well tolerated at a dose of 10 mg/kg administered intravenously every 2 weeks. Serious treatment-related adverse events were reported in 5 patients (6%), but no grade 4 adverse events or treatment-related deaths were reported. Preliminary data evaluating avelumab in chemotherapy-naive patients is also encouraging.
阿维鲁单抗是一种有前景的新型治疗药物，用于治疗转移性默克尔细胞癌患者，默克尔细胞癌是一种罕见且侵袭性强的皮肤神经内分泌肿瘤。在美国食品药品监督管理局最近批准阿维鲁单抗（巴文西奥）之前，没有治疗方法被批准用于治疗转移性默克尔细胞癌。在最近一项试验中，抗程序性死亡配体1抗体阿维鲁单抗在88例晚期、化疗难治性默克尔细胞癌患者中有28例（31.8%[95.9%CI，21.9 - 43.1]）出现客观缓解。总体而言，每2周静脉注射一次10mg/kg剂量的阿维鲁单抗耐受性良好。5例患者（6%）报告了严重的治疗相关不良事件，但未报告4级不良事件或治疗相关死亡。评估阿维鲁单抗在未接受过化疗患者中的初步数据也令人鼓舞。
